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Introduction: To determine the prevalence and clinical/laboratory associations of subclinical atherosclerosis and
impaired bone health in primary Sjogren’s syndrome (SS).
Methods: 64 consecutive patients with primary SS, 77 with rheumatoid arthritis (RA) and 60 healthy controls (HC)
οf similar age and sex distribution were enrolled. Demographics, clinical/laboratory features, classical risk factors for
atherosclerosis and osteoporosis (OP) were recorded. Intima-medial thickness scores (IMT) and carotid/femoral (C/F)
plaque formation, as well as bone mineral density (BMD) and fractures were evaluated. Determinants of IMT/BMD
levels and the presence of plaque were assessed by univariate and multivariate models. Serum levels of the Wnt
signaling mediators Dickkopf-related protein 1(DKK1) and sclerostin were determined in primary SS patients and HC.
Results: Increased arterial wall thickening (IMT > 0.90 mm) and impaired bone health (defined as OP or osteopenia),
were detected in approximately two-thirds of primary SS and RA patients, with a mean IMT value being significantly
increased compared to HC. The presence of primary SS emerged as an independent risk factor for arterial wall thickening
when traditional risk factors for cardiovascular disease (CVD) including age, sex, hypertension, smoking (pack/years), LDL
and HDL levels were taken into account in a multivariate model [adjusted OR 95% (CI): 2.8 (1.04-7.54)]. In primary SS, age
was revealed as independent predictor of increased IMT scores; age and lymphopenia as well as increased urine pH as
independent determinants of C/F plaque formation and OP/osteopenia, respectively. An independent association of
OP/osteopenia with plaque formation was observed when independent predictors for both variables were considered,
with low DKK1 levels being associated with both plaque formation and lower BMD levels.
Conclusions: Comorbidities such as subclinical atherosclerosis and impaired bone health occur frequently in primary SS,
in association with disease related features and traditional risk factors. Wnt signaling mediators are potentially involved in
the pathogenesis of both entities.Introduction
Increased rates of subclinical atherosclerosis have been
previously described in systemic autoimmune diseases,
particularly in systemic lupus erythematosous (SLE) and
rheumatoid arthritis (RA) [1-4]. However, traditional car-
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stated.body mass index (BMI), do not fully account for the high
rates of subclinical atherosclerosis in these patients [5-7].
Additionally, osteopenia and osteoporosis (OP) rates, which
have been found to be associated with surrogate markers of
cardiovascular comorbidity in healthy populations [8], have
been also shown to be increased in patients with SLE, RA
and systemic sclerosis [9-11].
Sjogren’s syndrome (SS) or autoimmune epithelitis is a
slowly progressing autoimmune disease characterized by
salivary and lacrimal gland dysfunction, resulting in oral
and ocular dryness. The syndrome shares many common
clinical features and serologic markers with other immune-
mediated autoimmune diseases, especially SLE [12,13]. Inl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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rather limited.
In the present study, we sought to determine the preva-
lence of subclinical atherosclerosis and impaired bone
health (OP or osteopenia) in patients with primary SS and
to explore whether they are associated with disease-related
features and with traditional risk factors for cardiovascular
disease (CVD) and OP. In addition, the Wingless-type
(Wnt) signaling pathway, which has been implicated in the




In the present prospective cohort study, 64 consecutive
patients with primary SS according to the American-
European Classification Criteria [16], 77 patients with
RA fulfilling the American College of Rheumatology
classification criteria for RA and 60 consecutive healthy
individuals (of similar age and sex distribution to the
patients with primary SS) were studied as disease and
healthy controls (HC), respectively. All patients were
followed at the Department of Pathophysiology, School
of Medicine, University of Athens and Department of
Rheumatology, General Hospital of Athens G. Gennimatas.
Exclusion criteria for all participants included preg-
nancy, age <18 years, renal dysfunction (serum creatin-
ine levels >3 mg/dl, creatinine clearance <30 ml/minute).
Serum was collected from patients and controls and
stored at −70°C. The study has been approved by the
Ethics Committee of Laikon General hospital and General
Hospital of Athens G. Gennimatas. All patients provided
written informed consent prior to their entry in the study.
Clinical assessment
Demographic data, clinical features, therapeutic regi-
mens and classical risk factors for atherosclerosis and
OP were recorded in all participating patients and con-
trols. Demographic data included age, sex, and BMI.
Clinical manifestations included the presence of sub-
jective and objective oral and ocular dryness (docu-
mented by unstimulated salivary flow rates and Schirmer’s
test/Rose Bengal staining, respectively) [16]; dry cough;
dyspareunia; fever; arthralgias; arthritis; carpal tunnel syn-
drome (documented by physical examination and nerve
conduction studies); Raynaud's phenomenon; lymphaden-
opathy; splenomegaly; purpura; pulmonary involvement
(small airway disease or interstitial lung disease docu-
mented by pulmonary function tests and high resolution
computed tomography scans); pleuritis; pericarditis; renal
involvement including interstitial nephritis (documented
by urine-specific gravity <1.010 or pH >5.5 on at least two
consecutive measurements after fluid restriction) and
glomerulonephritis documented by renal biopsy; liverinvolvement (documented by liver biopsy showing
changes compatible with primary biliary cirrhosis in the
setting of increased liver enzymes or anti-mitochondrial
antibodies); peri-epithelial disease (defined as peribron-
chial, interstitial nephritis, autoimmune cholangitis); myo-
sitis (documented by muscle biopsy in the setting of
increased aldolase or creatinophosphokinase); peripheral
neuropathy (documented by nerve conduction studies in
patients with clinical symptoms or signs suggestive of
neuropathy); central nervous involvement; lymphoma
(documented by biopsy) and other neoplastic diseases.
Sjogren’s syndrome disease activity index (ESSDAI) was
also determined [17].
Classical risk factors for atherosclerosis and OP included
the presence of family history of coronary disease (defined
as a cardiovascular episode occurring below the age of
55 years in men and below 65 years in women in first-
degree relatives); family history of low-energy fracture;
past medical history (PMH) of coronary heart disease,
stroke, DM, HT, low-energy fractures, malabsorption, or
thyroid function abnormalities; smoking history; alcohol
consumption (units/weeks); age of menarche and meno-
pause (for women) and total/current steroid use.
Hematological, biochemical and immunological parameters
Full blood count results, Westergren erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP) levels (cut off
value 5 mg/l) and kidney, liver and thyroid function
tests were recorded. Additionally, plasma levels of total
cholesterol and high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, triglycer-
ide, homocysteine and fibrinogen levels were determined
for all patients and controls, after overnight fasting. Serum
and 24-hour urine calcium and phosphorus levels, intact
parathyroid hormone (PTH) (pg/ml) and 25 (hydroxy)
vitamin D (25(OH) D3) (ng/ml) levels were also measured.
Immunological profile testing included antinuclear
antibodies (ANA), antibodies to Ro (SSA) and La (SSB)
antigens, complement levels, rheumatoid factor (RF) and
second-generation anti-cyclic citrullinated peptide anti-
body (only in RA patients); hypergammaglobulinemia
(total gamma globulins >2 g/l) and cryoglobulins.
Wnt signaling pathway
To determine whether the Wnt signaling pathway is im-
plicated in the concomitant presence of CVD and im-
paired bone health in patients with primary SS, serum
levels of Dickkopf-related protein 1 (DKK1) and sclerostin
were also determined in available sera from 59 patients
with primary SS and 17 HC by commercial ELISA, as per
manufacturer instructions (R&D Systems, Minneapolis,
MN, USA). According to these results, SS patients were
further subdivided in those characterized by low and high
DKK1 and sclerostin levels. As a cut off value was
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2403.6 pg/ml and sclerostin levels 212.2 pg/ml).
Assessment of subclinical atherosclerosis
The presence of subclinical atherosclerosis was defined by
the presence of plaque and/or arterial wall thickening
(defined as intima media thickness (IMT) score >0.90 mm
in carotid and femoral arteries as determined by ultra-
sound (iU22, Philips, Royal Philips Electronics of the
Netherlands)) [18]. Both the carotid (common carotid, bi-
furcation, and internal carotid) and the femoral (common
femoral and superficial femoral) arteries were evaluated in
each individual. The mean carotid artery IMT was defined
as the average of 36 IMT readings (common, bifurcation,
and internal carotid arteries, right and left side, far and
near wall, with three sampling points per segment) and the
mean femoral artery IMT was the average of twenty-four
IMT readings (common and superficial femoral arteries,
right and left side, far and near wall, with three sampling
points per segment), as previously described [19]. Plaque
formation was defined as a focal protrusion of more than
50% of the surrounding wall [20,21]. The radiologist (EA)
in charge of the ultrasound scanning was unaware of the
clinical diagnosis of the subjects under evaluation.
Bone mineral density (BMD) measurements
BMD measurements were performed in all patients and
controls by dual-energy x-ray absorptiometry using the
QDR4500 densitometer (Hologic, Bedford, MA, USA),
and were cross calibrated. On the basis of the individual’s
age, BMD determination was performed either on the hip
(total hip region) or the spine (anteroposterior lumbar
spine, lumbar vertebrae L1 to L4), for ages above or below
65 years, respectively, according to previously published
guidelines [22]. The presence of OP or osteopenia was de-
fined according to the World Health Organization (WHO)
classification system, as a T-score < −2.5 SD and −1 SD, re-
spectively, at either the lumbar spine or the hip [23].
Statistical analysis
Two-sided Fisher’s exact/chi-square and Mann–Whitney
tests were implemented to compare qualitative and quanti-
tative characteristics, respectively, between patient groups
and HC (Graph Pad Prism 5.00, GraphPad Software, San
Diego, CA, USA). In order to explore the independent con-
tribution of SS itself to the increased IMT levels, a multi-
variate model was constructed including age, sex, HT,
smoking (pack/years), LDL and HDL. Determinants of ar-
terial wall thickening (defined as IMT >0.90 mm) and
plaque, and the presence of OP or osteopenia in the setting
of SS and RA were assessed by univariate and multivariate
models. Multivariate models included the traditional risk
factors for CVD or OP/osteopenia, and disease-related fea-
tures that were found to be significant in univariateanalysis. In order to test whether the presence of plaque
formation was independently associated with the presence
of OP/osteopenia in primary SS and RA, another model
was constructed including well-established common risk
factors for both plaque formation and impaired bone health
such as age, total steroid dose and history of smoking. A P-
value <0.05 for univariate analyses and <0.1 for multivariate
analyses, respectively, were considered statistically signifi-
cant. Data were stored in the SPSS statistical package.
Results
Demographics - traditional risk factors for CVD and OP
Table S1 summarizes the demographic characteristics
and prevalence of traditional risk factors for CVD and
OP in patients with primary SS or RA, and in age- and
sex-matched HC (see Additional file 1). As shown, the
age distribution and sex ratio did not differ significantly
among the three groups. Patients with primary SS had a
mean age of 57.2 ± 12.4 years, a female-to-male ratio of
15 to 1 and disease duration of 8.4 ± 7.0 (mean ± SD)
years. Patients with RA had a mean age of 58.4 ±
11.3 years, a female-to-male ratio of 14.6 to 1.0 and dis-
ease duration of 14.8 ± 11.0 years, which was signifi-
cantly higher compared to the primary SS group. The
corresponding values for HC were 56.4 ± 7.8 years and
the female-to-male ratio was 14 to 1.
In regard to traditional CV and OP risk factors, compared
to the HC group, patients with primary SS had lower chol-
esterol levels and reduced rates of family history of CVD
(mean ± SD 194.6 ± 34.2 mg/dl versus 211.8 ± 32.2 mg/dl;
P = 0.01, 14.2% versus 28.8%; P = 0.04 respectively). Com-
pared to the RA group, patients with primary SS had
smaller disease duration (8.4 ± 7.03 versus 14.8 ± 11.0 years;
P = 0.0004), reduced current daily steroid dose intake
(1.3 ± 2.2 mg versus 4.8 ± 4.7 mg; P = 0.0001), lower serum
triglyceride (103.7 ± 43.1 mg/dl versus 124.7 ± 53.8 mg/dl;
P = 0.01) and CRP levels (4.6 ± 10.7 mg/l versus 14.8 ±
27.9 mg/l; P <0.0001) as well as higher 25(OH) vitamin
D and phosphate levels (21.3 ± 11.4 ng/ml versus 17.5 ±
7.1 ng/ml; P = 0.04 and 3.3 ± 0.5 mg/dl versus 3.1 ±
0.5 mg/dl; P = 0.01, respectively). On the other hand, RA
patients demonstrated increased rates of DM (14.1% ver-
sus 0%, P = 0.002), significantly elevated triglyceride levels
(124.7 ± 53.8 mg/dl versus 104.8 ± 53.2 mg/dl; P = 0.001),
lower serum phosphate and 25(OH)D3 levels (3.1 ±
0.5 mg/dl versus 3.4 ± 0.4 mg/dl; P = 0.0008, 17.5 ± 7.1 ng/
ml versus 22.2 ± 7.1 ng/ml; P = 0.0009) and increased CRP
levels compared to HC (14.8 ± 27.9 mg/l versus 2.7 ±
2.3 mg/l; P = 0.0004, respectively).
Prevalence of comorbidities in patients with primary SS
or RA and in age- and sex-matched healthy individuals
Increased IMT scores were detected in patients with pri-
mary SS and RA compared to HC (mean ± SD 1.0 ± 0.3
Gravani et al. Arthritis Research & Therapy  (2015) 17:99 Page 4 of 13and 1.0 ± 0.4 versus 0.9 ± 0.2; P = 0.03 and P = 0.002, re-
spectively) (Figure 1, Table 1). Additionally, the rates of
arterial wall thickening (defined as IMT >0.90 mm), ca-
rotid and femoral plaque formation, OP/osteopenia and
low-energy fractures are displayed in Table 1. The pre-
valence of arterial wall thickening was found to be
increased in primary SS compared to the HC group
(59.4% versus 40.4%, odds ratio (OR) 2.2, 95% CI 1.02,
4.55; P <0.05). Of interest, the presence of primary SS
emerged as an independent risk factor for arterial wall
thickening when traditional risk factors for CVD including
age, sex, HT, smoking (pack/years), LDL and HDL levels
were taken into account in a multivariate model (adjusted
OR 2.8, 95% CI 1.04, 7.54). Similar results were obtained
for RA patients compared to HC (data not shown).
Additionally patients with RA (but not with SS) differed
from HC in regard to plaque formation, OP/osteopenia
and fractures (84.4% versus 56.9, P <0.001, 72.2% versus
50.9, P <0.05 and 23.9% versus 8.5, P <0.05, respectively).
Compared to patients with primary SS, those with RA
exhibited significantly higher rates of plaque formation
and OP (84.4 versus 68.8, P <0.05 and 18.1% versus 7.8%,
P <0.05, respectively).
Associations between IMT levels and traditional risk
factors for CVD and disease-related features in patients
with primary SS
We next wished to identify predictors of arterial wall thick-
ening in the setting of primary SS. In the primary SS group,
a statistically significant association was observed between
IMT levels and traditional CVD risk factors including age,
BMI, HT, LDL and uric acid levels. Among disease-relatedFigure 1 Intima media thickness (IMT) scores in patients with
primary Sjogren's syndrome (SS) versus rheumatoid arthritis (RA) and
healthy controls (HC). Increased IMT scores were detected in patients
with primary SS or RA compared to HC (mean ± SD 1.0 ± 0.3 and
1.0 ± 0.4 versus 0.9 ± 0.2; P = 0.03 and P = 0.002, respectively).features, the presence of peri-epithelial disease, increased
levels of C3 and decreased urine specific gravity were also
found to be significantly associated with increased IMT
scores (see Table 2). Multivariate analysis revealed only
age as independent predictor of arterial wall thickening
in the setting of primary SS (OR 1.1, 95% CI 1.1, 1.2;
P = 0.002). No statistical significant associations were de-
tected between total steroid dose and IMT score in pri-
mary SS (r = −0.07; P = 0.57, Spearman’s rank correlation).
Predictors of plaque formation in patients with primary SS
The presence of carotid and/or femoral artery plaque in the
univariate analysis was positively associated with age, the
focus score on minor salivary gland biopsy and Raynaud’s
phenomenon, and was negatively associated with whole
salivary flow rates and lymphocytic numbers (Table 3).
Multivariate analysis confirmed age and absolute number
of lymphocytes as independent predictors of plaque for-
mation in the context of primary SS (OR 1.1, 95% CI 1.0,
1.1 and OR 0.9, 95% CI 0.9, 1.0, respectively).
Determinants of OP and/or osteopenia in patients with
primary SS
In univariate analysis the classical risk factors of age and
serum calcium levels were identified to be positively as-
sociated with the presence of OP and/or osteopenia in
patients with primary SS. Additionally, patients with evi-
dence of either osteopenia or OP exhibited lower rates
of a positive family history of fracture, increased preva-
lence of arthralgia and higher mean values of urine pH.
In multivariate analysis serum calcium and increased
urine pH emerged as independent predictors of OP or
osteopenia among patients with primary SS (OR 3.2,
95% CI 1.01, 10.4) and OR 4.5, 95% CI 1.004, 20.4, re-
spectively) (Table 4).
Further analysis of the prevalence of OP and/or osteope-
nia was subsequently carried out by subdividing the pa-
tients with primary SS according to the urinary pH levels
(cut off 5.5). According to this subgroup analysis, the pa-
tients with primary SS who had urinary pH >5.5 at the first
visit exhibited significantly increased rates of OP or osteo-
penia compared to those with urinary pH <5.5 (94.3% ver-
sus 44.4%, P = 0.002) (Additional file 2: Figure S1).
In a subset of 57 patients with primary SS, urine levels
of type 1 cross-linked c-telopeptide (CTX) were deter-
mined; no statistical significant associations were de-
tected between CTX levels, BMD levels, total steroid
dose and SS-activity index as analyzed by Spearman’s
rank correlation (data not shown).
Independent association of impaired bone health with
atherosclerotic plaque formation in patients with primary SS
Given the previously reported associations between alter-
ations in bone mass with atherosclerotic risk in healthy
Table 1 Prevalence of comorbidities in patients with primary SS or RA and in age- and sex-matched healthy
individuals
SS (n = 64) RA (n = 77) HC (n = 60) P-value* P-value** P-value***
Arterial wall thickening (IMT >0.90 mm), % 59.4 63.8a 40.4 ns <0.05 <0.01
IMT levels, mean ± SD 1.0 ± 0.3 1.0 ± 0.4a 0.9 ± 0.2 ns <0.05 <0.01
Presence of plaque, % 68.8 84.4 56.9 <0.05 ns <0.001
Osteopenia, % 51.6 54.2a 36.8 ns ns ns
Osteoporosis, % 7.8 18.1a 14.0 ns ns ns
Osteoporosis/osteopenia, % 59.4 72.2a 50.9 ns ns <0.05
Fractures, % 12.5 23.9a 8.5 ns ns <0.05
*Primary Sjogren's syndrome (SS) versus rheumatoid arthritis (RA); ** primary SS versus healthy controls (HC); *** RA versus HC; aanalysis based on 72 patients
with RA. IMT, intima media thickness; ns, not significant.
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an autoimmune population, such as patients with primary
SS [24,25]. In fact, the presence of either OP or osteopenia
in our SS study group was found to be strongly associated
with the presence of plaque, as detected by carotid and
femoral ultrasound (OR 4.0, 95% CI 1.3, 12.2; P = 0.01)
with 80% of patients with plaque having evidence of im-
paired bone health versus 20% of those with no plaque
(Figure 2A). This association remained significant when
classical predictors of both clinical entities, such as age,
total steroid dose and smoking, were included in the
multivariate model.
In order to investigate whether the Wnt signaling sys-
tem was involved in the concomitant occurrence of both
atherosclerotic and osteoporotic disease in our SS pa-
tients, DKK1 and sclerostin levels were also determined
by commercial ELISA. A positive correlation between
sclerostin and DKK1 levels with neck BMD levels was
detected (r = 0.42; P = 0.02 and r = 0.41; P = 0.01, respect-
ively). However, no association was found between scler-
ostin levels and the presence of atherosclerotic plaque
formation (data not shown). On the other hand, patients
with primary SS characterized by low DKK1 levels com-
pared to those with high DKK1 levels had reduced bone
mass levels (0.7 ± 0.1 versus 0.9 ± 0.1 mg/cm2) and in-
creased rates of plaque formation (81.8% versus 53.3%),
implying Wnt signaling as a potential contributor for the
concomitant presence of both comorbidities in a sub-
group of patients with primary SS (Figure 2B and C).
Associations between IMT levels and plaque formation
with traditional risk factors for CVD and disease-related
features in RA patients
In univariate analysis, arterial wall thickening among RA
patients was identified to be positively associated with
age, BMI, triglyceride levels, number of tender joints
and blood urea nitrogen (BUN) levels, and negatively
associated with cyclosporine treatment, CRP levels and
number of platelets/mm3. Age, BMI, the number of
tender joints and cyclosporine use were identified asindependent predictors of arterial wall thickening in
the setting of RA in multivariate analysis (see Additional
file 1: Table S2). No statistically significant associations
were detected between total steroid dose and IMT score
in the RA population (r = 0.20; P = 0.89, Spearman’s rank
correlation).
RA patients with carotid and/or femoral artery plaque
were older, with higher BMI, higher cumulative steroid
doses and BUN levels and increased rates of HT com-
pared to those without plaque formation. Paradoxically,
plaque formation was negatively associated with history
of smoking among RA patients in univariate analysis
(see Additional file 1: Table S3). Multivariate analysis
confirmed age and total steroid dose as independent
predictors of plaque formation in the context of RA.
Determinants of OP and/or osteopenia in RA patients
In both univariate and multivariate analysis, increased age,
PMH of fracture and increased PTH were identified to be
positively associated with the presence of OP and/or
osteopenia in RA patients (see Additional file 1: Table S4).
Discussion
In the present study we wished first to determine the
prevalence of comorbidities such as subclinical athero-
sclerosis and impaired bone health in a cohort of patients
with primary SS compared to healthy and RA individuals
with a similar age/sex distribution, and second, to explore
potential associations with disease-related features and
traditional risk factors for CVD and OP. We have shown
that the presence of primary SS was as an independent
risk factor for arterial wall thickening, when traditional
risk factors for CVD including age, sex, HT, smoking
(pack/years), LDL and HDL levels were taken into account
in a multivariate model. While the carotid/femoral ΙΜΤ
levels were found to be significantly higher in primary SS
and RA patients versus HC, only RA patients demon-
strated increased rates of plaque formation compared to
both SS patients and HC. The higher proportion of DM
and the increased triglyceride and CRP levels, together
Table 2 Traditional and disease-related predictors of arterial wall thickening in patients with primary SS
Univariate analysis Multivariate analysis
IMT >0.90 (n = 38) IMT ≤0.90 (n = 26) P-value Odds ratio (95% CI) P-value
Traditional risk factors
Age, years 62.5 ± 9.2 49.8 ± 12.6 <0.001 1.1 (1.1, 1.2) 0.002
Female, % 92.1 96.2 ns
Past medical history of CVD, % 7.9 3.8 ns
Family history of CVD, % 13.2 15.4 ns
Smoking, packs/year 10.5 ± 20.7 3.6 ± 7.4 ns
Body mass index 29.0 ± 5.7 25.0 ± 4.4 0.02
Diabetes, % 5.3 7.7 ns
Hypertension, % 47.4 19.2 0.04
Cholesterol levels, mg/dl 202.2 ± 35.2 183.8 ± 30.0 ns
High-density lipoprotein, mg/dl 57.0 ± 13.9 53.5 ± 15.5 ns
Low-density lipoprotein, mg/dl 126.8 ± 32.2 111.2 ± 25.0 0.03
Triglycerides, mg/dl 111.5 ± 44.7 92.5 ± 38.8 ns
Homocysteine levels, μmol/l 14.6 ± 4.6 14.2 ± 6.0 ns
Uric acid, mg/dl 4.4 ± 1.1 3.6 ± 1.2 0.006
Current steroid dose, mg 1.3 ± 2.3 1.1 ± 2.1 ns
Total steroid dose, g 7.8 ± 17 6.6 ± 11.3 ns
Current TSH levels, μ ΙU/dl 1.5 ± 1.4 1.8 ± 1.3 ns
C-reactive protein, mg/l 3.1 ± 3.2 6.7 ± 16.0 ns
Fibrinogen, mg/dl 416.6 ± 108.2 395.6 ± 128.1 ns
25-hydroxy vitamin D3, ng/ml 22.3 ± 13.4 19.8 ± 7.6 ns
Disease-related features
Disease duration, years 8.7 ± 7.4 8.0 ± 6.6 ns
SS disease activity index 1.8 ± 1.5 1.8 ± 1.7 ns
Focus score, number of foci/4 mm2 2.6 ± 2.2 1.6 ± 1.4 ns
Whole salivary flow, ml/15 minutes 2.0 ± 2.8 2.6 ± 3.1 ns
Peri-epithelial disease, % 31.6 3.8 0.007
Arthritis, % 23.6 46.1 ns
Arthralgias, % 65.7 76.9 ns
Dry mouth, % 84.2 76.9 ns
Dry eyes, % 86.8 88.5 ns
Salivary gland enlargement, % 21.1 15.3 ns
Raynaud’s phenomenon, % 28.9 23.1 ns
Lymphadenopathy, % 18.4 19.2 ns
Splenomegaly, % 2.6 3.8 ns
Palpable purpura, % 10.5 3.8 ns
Monoclonal gammopathy (%) 10.5 3.8 ns
Cryoglobulins (%) 2.6 0 ns
Lymphoma (%) 18.4 7.6 ns
Antinuclear antibodies >1/160, % 89.4 96.1 ns
Anti-Ro/SSA, % 76.3 73.1 ns
Anti-La/SSB, % 42.1 57.7 ns
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Table 2 Traditional and disease-related predictors of arterial wall thickening in patients with primary SS (Continued)
Rheumatoid factor titers, IU/ml 61.0 ± 104 58.3 ± 84.0 ns
Complement 3, mg/ml 1.2 ± 0.2 1.1 ± 0.2 0.002
Complement 4, mg/ml 0.2 ± 0.1 0.2 ± 0.1 ns
Absolute number of WBC/mm3 5,647 ± 1903 5,727 ± 1785 ns
Absolute number of lymphocytes/mm3 1,518 ± 463 1,645 ± 756 ns
Erythrocyte sedimentation rate 34 ± 21 31 ± 22 ns
γ-globulins, % 18.5 ± 5.2 18.6 ± 3.4 ns
Urine specific gravity 1,013 ± 6 1,018 ± 8.0 0.007
Urine pH 6.1 ± 0.7 6.1 ± 0.6 ns
IMT, intima media thickness; SS, Sjogren’s syndrome; IMT, Intima media thickness; CVD, cardiovascular disease; TSH, thyroid stimulating hormone; WBC, white
blood cells; ns, not significant.
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could account for the pronounced atherosclerotic risk in
these patients, as previously reported [26-28].
We next aimed to explore whether disease-related and/
or traditional risk factors could account for the increased
rates of comorbidities among patients with primary SS.
Advanced age, higher hypertension rates and BMI, in-
creased LDL and uric acid levels and the presence of peri-
epithelial disease were found to be associated with arterial
wall thickening, while advanced age, higher focus score on
minor salivary gland biopsy and reduced salivary flow
rates, the presence of Raynaud’s syndrome and reduced
lymphocytic numbers were predictors of plaque for-
mation. In multivariate models, age was an independent
predictor of both arterial wall thickening and plaque for-
mation, and lymphopenia was an independent risk factor
for plaque formation. Although increased prevalence of
DM [29], hypertriglyceridemia [29,30], HT [30] and dys-
lipidemia [31,32] were previously reported to be higher
among SS populations, we have not observed significant
differences between patients with primary SS and HC,
except for lower rates of family history of CVD and chol-
esterol levels in the primary SS group. The latter observa-
tion was also supported by Lodde et al. [33].
Although the increased atherosclerotic risk is well-
established in patients with SLE [34], RA [35] and
systemic sclerosis [36], a limited body of evidence is
available on primary SS syndrome. Vaudo et al., ob-
served increased carotid and femoral IMT scores in
white women with primary SS compared to age- and
sex-matched HC in association with leucopenia and the
presence of anti-SSA antibodies [18,19]. Although no asso-
ciation with anti-Ro/SSA antibodies and IMT values was
detected in our cohort, we also revealed lymphopenia as a
significant predictor of plaque formation in our patient
group. Additionally, endothelial dysfunction identified by
abnormal ankle brachial index (ABI), lower endothelium-
dependent flow-mediated vasodilatation (FMV), increased
asymmetric dimethylarginine (ADMA) and higher pulsewave velocity (PWV) values were recently demonstrated
[37-39]. At the time of preparation of the current manu-
script, data from a large multicenter Italian study demon-
strated an increased risk of cerebrovascular events and
myocardial infarction among primary SS populations [32].
On the other hand, impaired smooth-muscle relaxation
was present in patients with primary SS independent of
endothelial contribution, and particularly in those charac-
terized by leucopenia, RF, anti-SSB antibodies and articular
involvement [38].
The mechanisms for the observed atherosclerotic risk in
SS have not yet been elucidated. Data derived mainly from
lupus studies suggest that T and B cell dysregulation
heightens production of cytokines such as inteleukin-17
(IL-17), interferon γ (ΙFNγ), and more recently interferon
α (ΙFNα), a central cytokine in both lupus and SS patho-
genesis, which have been all considered to contribute to
the increased cardiovascular risk of these patients. Particu-
larly, impairment of endothelial repair through accelerated
apoptosis of endothelial progenitor cells, together with en-
hancement of foam cell formation in the atherosclerotic
plaque, have been proposed to account for the atherogenic
potential of IFNα [40].
Age, BMI and clinical variables of disease activity as
evidenced by increased number of tender joints were
independent predictors of increased IMT scores in the
RA group, whereas cyclosporine use had a protective
role against arterial wall thickening among these pa-
tients, in line with previous observations in SLE pa-
tients, in which use of cyclosporine A protected against
increased carotid IMT, leading to a decreased risk of
arteriosclerosis [41]. Plaque formation was independ-
ently associated with age and total steroid dose, in line
with previous observations [42].
Although an increased risk of OP and fracture rates in
autoimmune diseases such as SLE [9], RA [43] and sys-
temic sclerosis [11] is well-documented, no information
is available on the occurrence of OP/osteopenia or frac-
ture rates in patients with primary SS. Patients with
Table 3 Traditional and disease-related predictors of plaque formation in patients with primary SS
Univariate analysis Multivariate analysis
Plaque (n = 44) No plaque (n = 20) P-value Odds ratio (95% CI) P-value
Traditional risk factors
Age, years 60.1 ± 9.1 51.0 ± 16.2 0.006 1.1 (1.0, 1.1) 0.09
Female, % 93.2 95 ns
Past medical history of CVD, % 6.8 5 ns
Family history of CVD, % 18.2 5 ns
Smoking, packs/year 9.1 ± 19.3 4.7 ± 9.3 ns
Body mass index 27.6 ± 5.6 26.8 ± 5.5 ns
Diabetes, % 9.1 0 ns
Hypertension, % 38.6 30.0 ns
Cholesterol levels, mg/dl 194.4 ± 33.9 194.9 ± 35.7 ns
High-density lipoprotein, mg/dl 56.6 ± 15.1 51.2 ± 12.8 ns
Low-density lipoprotein, mg/dl 116.1 ± 30.6 130.2 ± 27.7 ns
Triglycerides, mg/dl 107.8 ± 43.9 93.9 ± 40.8 ns
Homocysteine levels, μmol/l 15.3 ± 5.5 12.4 ± 3.8 ns
Uric acid, mg/dl 4.1 ± 1.3 4.0 ± 0.9 ns
Current steroid dose, mg 1.3 ± 2.2 1.1 ± 2.2 ns
Total steroid dose, g 9.3 ± 17.5 3.7 ± 6.3 ns
Current TSH levels, μ ΙU/dl 1.6 ± 1.5 1.6 ± 1.2 ns
C-reactive protein, mg/l 3.2 ± 5.8 7.6 ± 17.0 ns
Fibrinogen, mg/dl 410.0 ± 99.7 402.8 ± 151.2 ns
25-hydroxy vitamin D3, ng/ml 21.1 ± 12.9 21.7 ± 7.0 ns
Disease-related features
Disease duration, years 8.9 ± 7.3 7.3 ± 6.6 ns
SS disease activity index 1.7 ± 1.5 2.1 ± 1.8 ns
Focus score, number of foci/4 mm2 2.7 ± 1.9 1.2 ± 1.4 0.04
Whole salivary flow, ml/15 minutes 1.9 ± 2.8 3.0 ± 3.2 0.04
Peri-epithelial disease, % 22.7 15.0 ns
Arthritis, % 29.5 40.0 ns
Arthralgias, % 68.2 75.0 ns
Dry mouth, % 84.1 75.0 ns
Dry eyes, % 90.9 80.0 ns
Salivary gland enlargement, % 11.4 20 ns
Raynaud’s phenomenon, % 34.1 10.0 0.04
Lymphadenopathy, % 18.2 20.0 ns
Splenomegaly, % 2.3 5 ns
Palpable purpura, % 9.1 5 ns
Cryoglobulins (%) 2.3 0 ns
Lymphoma (%) 13.6 15.0 ns
Antinuclear antibodies >1/160, % 86.4 95 ns
Anti-Ro/SSA, % 72.7 75 ns
Anti-La/SSB, % 47.7 50.0 ns
Rheumatoid factor titers, IU/ml 53.7 ± 88.7 72.5 ± 108.6 ns
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Complement 3, mg/ml 1.1 ± 0.2 1.2 ± 0.3 ns
Complement 4, mg/ml 0.2 ± 0.1 0.2 ± 0.1 ns
Absolute number of WBC/mm3 5,533 ± 1968 6,006 ± 1516 ns
Absolute number of lymphocytes/mm3 1,411 ± 476 1,924 ± 705 0.001 0.9 (0.9, 1.0) 0.02
Erythrocyte sedimentation rate 33 ± 21 31 ± 21 ns
γ-globulins, % 18.3 ± 5.1 19.0 ± 2.7 ns
Urine specific gravity 1,014 ± 6 1,016 ± 9 ns
Urine pH 6.1 ± 0.7 6.1 ± 0.5 ns
IMT, intima media thickness; SS, Sjogren’s syndrome; IMT, Intima media thickness; CVD, cardiovascular disease; TSH, thyroid stimulating hormone; WBC, white
blood cells; ns, not significant.
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features which theoretically predispose to low bone
mineralization; these include low vitamin D levels, hy-
percalciuria related to underlying interstitial nephritis,
steroid use for systemic involvement, and coexistence
with other organ-specific autoimmune disorders knownTable 4 Determinants of osteoporosis (OP) or osteopenia in p
Univariate analysis
Presence of osteoporo
or osteopenia (n = 38)
Classical risk factors for osteoporosis
Age, years 59. 9 ± 10.1
Family history of fracture, % 5.4
Past medical history of fracture, % 15
Body mass index 26.9 ± 4.7
Age of menarche, years 13.4 ± 1.7
Age of menopause, years 49.4 ± 4.1
Calcium, mg/dl 9.7 ± 0.5
Phosphate, mg/dl 3.4 ± 0.5
Calcium urine/24 h, g 0.1 ± 0.1
Phosphate urine/24 h, g 0.5 ± 0.2
25-hydroxy-vitamin D3, ng/ml 21.2 ± 12.9
Parathyroid hormone, pg/ml 50.2 ± 22.6
Current thyroid stimulating hormone levels (μ IU/dl) 1.34 ± 2.1
Total steroid dose, g 9.8 ± 17.8
Current steroid dose, mg/day 1.6 ± 2.4
Disease-related features
Sjogren's syndrome activity index 1.85 ± 1.49
Disease duration, years 9.1 ± 7.4
Focus score, number of lymphocytic foci/4 mm2 1.9 ± 1.8
Whole salivary flow, ml/15 minutes 2.0 ± 2.9
Urine pH 6.3 ± 7.4
Urine specific gravity 1,014 ± 6.9
Arthralgias, % 80
Peri-epithelial disease, % 27.5
ns, not significant.to increase OP risk, such as primary biliary cirrhosis and
celiac disease [44-46]. In our hands, the rate of positive
antimitochondrial as well as antigliandin and antitrans-
glutaminase antibodies, respectively, was low, and there-
fore firm conclusions cannot be drawn (data not shown).
In regard to OP/osteopenia and fracture rates and inatients with primary SS
Multivariate analysis
sis Absence of osteoporosis
or osteopenia (n = 24)
P-value Odds ratio 95% (CI) P-value
52.8 ± 14.6 0.03
27.2 0.02
8.3 ns
28.2 ± 6.8 ns
13.1 ± 2.4 ns
50.6 ± 6.3 ns
9.3 ± 0.6 0.02 3.2 (1.01, 10.4) <0.05
3.2 ± 0.6 ns
0.1 ± 0.2 ns
0.6 ± 0.2 ns
21.4 ± 8.1 ns
41.6 ± 16.6 ns
1.3 ± 1.5 ns
3.2 ± 0.5 ns
0.5 ± 1.4 ns
1.74 ± 1.8 ns
7.3 ± 6.3 ns
2.4 ± 1.9 ns
2.6 ± 3.1 ns
5.8 ± 0.4 0.03 4.5 (1.004, 20.4) <0.05
1,015 ± 7 ns
54.2 0.03
8.3 ns
Figure 2 Independent association of osteopenia/osteoporosis (OP) with atherosclerotic plaque formation in patients with primary Sjogren's
syndrome (SS). (A) Association of osteopenia/OP with plaque formation in SS (odds ratio (OR) 4.0, 95% CI 1.3, 12.2, P = 0.01). This association
remained significant when potential confounders for both clinical entities, such as age, total steroid dose and smoking, were taken in consideration.
(B) Patients with primary SS characterized by low Dickkopf-related protein 1 (DKK1) levels had reduced bone mass levels compared to those with high
DKK1 levels (0.7 ± 0.1 versus 0.9 ± 0.1 mg/cm2, P = 0.002). (C) Similarly, patients with primary SS with low DKK1 levels had increased rates of plaque
formation (81.8% versus 53.3%). The sum of the mean + 2 SD of healthy controls (HC) (2403.6 pg/ml) was considered as the cut off value for low and
high DKK1 levels.
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ferences were observed between primary SS group as a
whole and the HC group. It was surprising that patients
with primary SS experienced paradoxically higher rates
of fractures compared to HC, despite the lower rates of
osteopenia. Given that the differences noted were notstatistically significant, we presume that this was a
chance finding.
When patients with primary SS were stratified accord-
ing to urine pH, which was an independent predictor of
OP and or/osteopenia in the multivariate analysis, sig-
nificantly increased prevalence of OP/osteopenia was
Gravani et al. Arthritis Research & Therapy  (2015) 17:99 Page 11 of 13observed compared to the controls. Although vitamin D
and serum phosphate levels were decreased in RA pa-
tients compared to HC, which might contribute to the
increased rates of OP and fracture risk in this popula-
tion, they were within normal limits within our SS co-
hort. Additionally, mean current steroid dose and CRP
levels as a marker of systemic inflammation, which was
previously implicated in osteoporotic risk among RA pa-
tients [47], were increased in our RA cohort, in which
independent predictors of OP/osteopenia included PMH
of fracture, increased serum levels of PTH and advanced
age, as previously reported [48].
A growing body of evidence over the last decade sup-
ports the association between bone mass reduction and
atherosclerotic risk in healthy populations [49,50]. In the
present study, we also observed the concomitant occur-
rence of decreased bone mass and plaque formation in
our autoimmune SS group, when potential confounders
for both clinical entities, such as age, total steroid dose
and smoking were considered. Such an association was
not detected in our RA cohort, possibly related to the
confounding effects of concomitant medications.
To further explore the underlying linking mechanisms
between impaired bone health and atherosclerotic risk in
primary SS, inhibitors of the Wnt signaling pathway
were measured, including sclerostin and DKK1, which
were previously potentially implicated in the pathogen-
esis of arterial calcification and/or inhibition of bone for-
mation [51-53]. In accordance with previously reported
findings in diabetic [52] and in predialysis patients with
chonic kidney disease [54], an inverse relationship was
identified between the levels of DKK1 and presence of
plaque formation in patients with primary SS. On the
other hand, BMD was positively associated with serum
sclerostin, as already suggested, as well as with DKK1
levels, an observation not previously reported [14]. A
plausible scenario for the current observations could be
that osteoporotic/osteopenic SS patients, characterized
by suppressed Wnt signaling, display paradoxically re-
duced DKK1 levels possibly due to the absence of a
negative feedback provided by Wnt inhibitors as pre-
viously suggested [14]. As a result, a lack of DKK1-
mediated protection against vascular wall calcification
could lead to plaque formation and increased athero-
sclerotic risk.
Conclusion
In conclusion, in the present study we demonstrated
that almost two thirds of patients with primary SS have
evidence of subclinical atherosclerosis and impaired
bone health, which may be attributed in part to the pres-
ence of traditional risk factors as well as disease-related
features, with Wnt pathway mediators possibly account-
ing for this observation. Further larger studies arewarranted to better explore the contribution of the Wnt
signaling pathway in the pathogenesis of these comor-
bidities in both healthy and autoimmune populations.
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